Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1. 1This trial is testing a GLP-1 analogue for people who have both Type 1 diabetes and obesity — given that GLP-1 drugs like semaglutide are mostly studied in Type 2 diabetes, what extra risks or unknowns should I be aware of when using one alongside my Type 1 diabetes management?
2. 2The trial is measuring changes in visceral fat, liver insulin resistance, and triglycerides over 12 months — based on my current levels of these markers, do you think I'd be a good candidate to potentially benefit from this kind of approach, and how would we even track those changes in my case?
3. 3Since this is a Phase 2 trial, the focus is still on understanding how well this works and refining safety data — what does that mean for how much we already know about the risks compared to if this were a later-stage study?
4. 4Could joining this trial interfere with or delay other treatments I might need for my Type 1 diabetes or obesity management, and is there a standard-of-care option we should consider trying first before enrolling in a research study?
5. 5The trial runs for 12 months, which is a significant commitment — what does participation actually look like day-to-day, and are there visit schedules, monitoring requirements, or adjustments to my insulin regimen that I should plan around?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.